ReviewOncoTargets and therapy2020
Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib.
Review in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A SEER derived prognostic nomogram identifies stage IV metastatic lung squamous cell carcinoma patients who may benefit from primary tumor resection.Discover oncology · 2026Article
- Impact of piR_004530 reactivation in lung cancer: implications for recurrence and survival of lung squamous cell carcinoma patients.BMC medicine · 2025Article
- Lymphoma combined with lung cancer: A case report.Respiratory medicine case reports · 2024Article
- Article
- KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.Cancer cell · 2023Article
- Pre-clinical lung squamous cell carcinoma mouse models to identify novel biomarkers and therapeutic interventions.Frontiers in oncology · 2023Review
- Construction and validation of a prognostic model based on ten signature cell cycle-related genes for early-stage lung squamous cell carcinoma.Cancer biomarkers : section A of Disease markers · 2023Article
- Circular RNA hsa_circ_0018189 drives non-small cell lung cancer growth by sequestering miR-656-3p and enhancing xCT expression.Journal of clinical laboratory analysis · 2022Article
- A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.Scientific reports · 2022Article
- PKP1 and MYC create a feedforward loop linking transcription and translation in squamous cell lung cancer.Cellular oncology (Dordrecht, Netherlands) · 2022Article
- Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism.Molecules (Basel, Switzerland) · 2021Review
- What's in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications.Journal of medicinal chemistry · 2021Review
- Development and Validation of an E2F-Related Gene Signature to Predict Prognosis of Patients With Lung Squamous Cell Carcinoma.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Options for the treatment of squamous cell lung carcinoma expanded in recent years with the introduction of the immune checkpoint inhibitors into routine clinical practice in both the first- and second-line settings but are still limited. As a result, pembrolizumab, given either alone or in combination with platinum-based chemotherapy, is now a standard first-line treatment for squamous cell lung cancer. However, few options exist once patients have progressed on immune checkpoint inhibitors and chemotherapy. In this setting, the irreversible ErbB family blocker, afatinib, has a potential role as second or subsequent therapy for some patients. The Phase III LUX-Lung 8 study demonstrated that afatinib significantly prolonged progression-free and overall survival compared with erlotinib in patients with squamous cell lung carcinoma. Notably, retrospective, ad-hoc biomarker analyses of a subset of patients from LUX-Lung 8 suggested that patients with ErbB family mutations derived particular benefit from afatinib, especially those with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.